Ethics Group Calls for Investigation of HHS Official Alicia Jackson
A nonpartisan ethics watchdog group has formally requested an investigation into whether Alicia Jackson, a prominent official at the Department of Health and Human Services (HHS), violated ethics laws. This call for scrutiny follows a ProPublica investigation that raised serious concerns about Jackson's actions, which experts have described as alarming and indicative of an obvious conflict of interest.
Jackson, who leads the Advanced Research Projects Agency for Health, publicly supported a change in federal health policy regarding hormone replacement therapies while simultaneously owning stock in Evernow, a company that provides access to menopause treatments. This dual role raises significant ethical questions about her ability to make unbiased decisions that could benefit her financial interests.
Common Sense Shop
The United States of Common Sense
Amazon shopping links. Sponsor Complete!
In a letter directed to the inspector general of the department, the Campaign Legal Center also scrutinized whether Jackson accurately disclosed up to $400 million in underlying assets linked to her husband’s investment firm. Furthermore, the review highlighted another potential conflict: investments in a second firm that also offers hormone treatments for menopause.
Recently, Jackson was placed on administrative leave, although HHS officials have not provided a public rationale for this action. The Campaign Legal Center's letter cited findings from the ProPublica investigation, noting that Jackson had spoken at an HHS press conference last November and was quoted in a department news release that announced the removal of “black box warnings” from hormone replacement therapy products.
At the time of her endorsement, Jackson reportedly held at least $115,000 in stock and an unspecified amount of stock options in Evernow, according to her financial disclosures. However, it remains unclear what influence, if any, Jackson had on the decision to eliminate the black box warning, which is the most severe type of federal safety warning. The Food and Drug Administration (FDA) oversees drug regulations, and an FDA expert panel had recommended this removal months prior to Jackson's appointment as director in October 2025.
Despite this timeline, ethics experts emphasize that federal law explicitly prohibits government employees from engaging “personally and substantially” in matters that could affect their personal financial interests, including making public statements at press conferences or in news releases. The Campaign Legal Center has urged the inspector general to investigate whether Jackson failed to recuse herself from the policy announcement, and neither she nor HHS has confirmed whether she received a conflict-of-interest waiver prior to her participation.
Concerns Over Financial Transparency in Government
“Americans deserve assurance that government decisions are not influenced by a federal employee’s financial interests,” the organization stated in its letter. Additionally, the center called for an examination of whether Jackson accurately disclosed her and her spouse’s financial interests in private investment funds.
ProPublica's investigation revealed that Jackson reported ownership of over 60 venture capital and private equity funds, which she claimed do not disclose their holdings to investors. Among these are at least 13 funds managed by 137 Ventures, a firm co-founded by her husband, Alex Jacobson, which invests across various sectors, including healthcare and medical devices.
Ethics experts caution that these funds could create serious conflicts of interest if the underlying businesses receive grants or contracts from Jackson's agency. The Campaign Legal Center identified one such fund, 137 Ventures IV LP, as an investor in Thirty Madison Inc., a virtual healthcare company that owns a subsidiary providing hormone replacement treatments for menopause. Jackson's disclosures do not indicate that she divested from this fund before the announcement regarding the black box warning.
Under federal law, financial disclosures filed by federal officials like Jackson must be certified by ethics staff to ensure compliance with the law. However, Jackson's two financial disclosures—one filed last October and another two months ago—remain uncertified. The HHS inspector general’s office has neither confirmed nor denied whether it is investigating Jackson. The inspector general, T. March Bell, was confirmed by the Senate in a party-line vote in December 2025, following the dismissal of the previous inspector general shortly after President Trump began his second term.
The Common Sense Test
ProPublica also sought comments from HHS, Jackson, Jacobson, and 137 Ventures, but received no responses. An HHS spokesperson stated that while Jackson is on leave, the agency would assess the facts before determining any changes to her status, emphasizing that all officials must adhere to federal ethics laws, regulations, and policies.
Jackson, appointed by Trump as the second director of her agency, was sworn in on October 20, 2025. The agency, established three years earlier to promote groundbreaking biomedical research and technologies, operates with a budget of $1.5 billion and has issued numerous contracts and grants, including $160 million for genetic medicines targeting rare diseases and $144 million to study existing treatments for age-related illnesses. Jackson's financial disclosures are part of a larger database of Trump administration officials' finances, which ProPublica has been compiling and updating as part of its commitment to transparency and accountability in government.




